A new article by Tyler Patchen writing for Biospace highlight how the BIOSECURE Act, a U.S. House bill that aims to restrict American biopharma companies from working with certain Chinese contract development and manufacturing organizations (CDMOs), particularly WuXi AppTec and WuXi Biologics will impact biopharma companies in the U.S. The...